- Generic name
- Levetiracetam
- Strength
- 250 mg
- Dosage form
- Tablet
- Manufactured by
- Synovia Pharma PLC.
Leveron 250 Tablet
About Leveron 250 Tablet
Leveron 250 250 mg is a tablet product of Synovia Pharma PLC. that contains Levetiracetam. It is prescribed for adults, adolescents, children and infants, depending on the doctor's assessment.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Leveron 250 Tablet?
The tablet Leveron 250 contains Levetiracetam and is made by Synovia Pharma PLC. It belongs to a group of medicines called adjunct anti-epileptic drugs, meaning it is added to other epilepsy treatment. Leveron 250 is a prescription medicine, so it should only be taken on a doctor's advice. The dose and course depend on the person's age, weight and response, and are decided by the doctor.
Uses of Leveron 250
It is prescribed for adults, adolescents, children and infants, depending on the doctor's assessment. Leveron 250 is used in the treatment of partial-onset seizures, which may or may not spread to affect the whole body. Your doctor will decide whether it suits your type of epilepsy.
How to use Leveron 250
Swallow the tablet as advised by your doctor or pharmacist. Leveron 250 is taken by mouth. Swallow the tablet with water. Do not take more than prescribed. The doctor decides the dose and how long you take it. If you miss a dose, ask your doctor or pharmacist for advice.
Side effects of Leveron 250
In children, fatigue, aggression, nasal congestion, decreased appetite and irritability have been reported. Some people may notice side effects while taking Leveron 250. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
Do not take Leveron 250 if you are allergic to Levetiracetam, other pyrrolidone derivatives, or any ingredient of the tablet. Leveron 250 250 mg tablet is not recommended during pregnancy or in women who could become pregnant and are not using contraception, unless the doctor decides it is clinically necessary. It passes into breast milk, so breastfeeding is generally not recommended; discuss this with the doctor. Tell your doctor about kidney or liver problems, because the dose may need adjusting.
Frequently asked questions
What is Leveron 250 used for?
It is prescribed for adults, adolescents, children and infants, depending on the doctor's assessment. Leveron 250 is used in the treatment of partial-onset seizures, which may or may not spread to affect the whole body.
How do I use Leveron 250 correctly?
Swallow the tablet as advised by your doctor or pharmacist. Leveron 250 is taken by mouth.
What should I watch for while using Leveron 250?
In children, fatigue, aggression, nasal congestion, decreased appetite and irritability have been reported. Some people may notice side effects while taking Leveron 250.
Who should be careful with Leveron 250?
Do not take Leveron 250 if you are allergic to Levetiracetam, other pyrrolidone derivatives, or any ingredient of the tablet. Leveron 250 250 mg tablet is not recommended during pregnancy or in women who could become pregnant and are not using contraception, unless the doctor decides it is clinically necessary.
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.